Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-01-28 @ 4:55 AM
Study NCT ID:
NCT03340493
Status:
COMPLETED
Last Update Posted:
2020-03-04
First Post:
2017-11-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
Sponsor:
Neuroscience Trials Australia
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Ischemic Stroke | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Stroke | View |
| None | Ischemia | View |
| None | Cerebral Infarction | View |
| None | Cerebrovascular Disorders | View |
| None | Brain Diseases | View |
| None | Central Nervous System Diseases | View |
| None | Nervous System Diseases | View |
| None | Vascular Diseases | View |
| None | Cardiovascular Diseases | View |
| None | Pathologic Processes | View |
| None | Brain Infarction | View |
| None | Brain Ischemia | View |
| None | Tenecteplase | View |
| None | Fibrinolytic agents | View |
| None | Fibrin Modulating agents | View |
| None | Molecular Mechanisms of Pharmacological Action | View |
| None | Plasminogen | View |
| None | Tissue Plasminogen Activator | View |